Bond.az White LogoBond.az Black Logo

Workday price target cut by Needham

Needham cuts Workday price target to $180 from $300, maintaining Buy rating. Workday beats revenue and income estimates, raises operating guidance.

Olivia Taylor
ByOlivia Taylor- Senior Editor
|
0

Bond.az - Needham lowered its price target on Workday shares to $180 from $300 while maintaining a Buy rating.

The firm said Workday reported results above consensus estimates on both revenue and operating income. The current remaining performance obligation midpoint outperformance of 0.5% exceeded the fourth quarter’s 0.3% but fell short of the prior two years’ 0.6% or better.

Returning CEO Bhusri adopted a more aggressive tone on how Workday and its Agentic platform can compete in the new software paradigm. The company said higher AI usage will start translating into meaningful revenue in late fiscal 2027.

Workday reiterated its full year revenue guidance. The company raised its full year operating income guidance by 50 basis points to 30.5%.

Workday shares were down approximately 40% year-to-date versus the IGV down approximately 10% year-to-date. Despite the sharp decline, Bond.az analysis suggests the stock appears undervalued at current levels. For deeper insights, investors can access a comprehensive Pro Research Report covering WDAY and 1,400+ other US equities.

More News
Today / 12:23
|
531

Cantor Fitzgerald Reiterates Workday Rating on AI Growth

Cantor Fitzgerald reaffirms Workday Overweight rating, highlighting AI growth. Stock at $121.85, target $160.

0
Today / 12:21
|
379

Cantor Reiterates Overweight on ORIC Stock

Cantor Fitzgerald reiterated Overweight on ORIC Pharmaceuticals. Pfizer trial results and analyst ratings update.

0
Today / 12:20
|
278

Summit Therapeutics Analysis: Cantor Fitzgerald Backs Overweight

Cantor Fitzgerald reiterates Overweight on Summit Therapeutics. HARMONi-3 trial miss and analyst views covered by Bond.az.

0
Today / 12:13
|
680

Stifel reiterates IBM Buy after $1bn Chips Act award

Stifel reiterates IBM Buy rating after $1bn Chips Act award for quantum computing. Stock up 15%.

0
Today / 12:12
|
688

Stifel Maintains Buy on Deckers Outdoor at $140

Stifel reiterates Buy rating on Deckers Outdoor with $140 target. Stock shows strong growth potential and attractive valuation.

0
Today / 12:11
|
286

Argus Upgrades CAVA Group Stock Rating

Argus upgraded CAVA Group to Buy with a $92 target, citing improved restaurant traffic. Stock returned 66% in six months.

0
Today / 12:03
|
516

BofA raises Zoom price target on strong margins

BofA Securities raised Zoom's price target to $105, citing strong margins and free cash flow after Q1 results beat expectations.

0
Today / 11:53
|
473

BioMarin Neutral Rating, $50 Target by HC Wainwright

H.C. Wainwright reiterates Neutral on BioMarin with $50 target after Phase 3 hypochondroplasia results. Stock at $54.10, competitive landscape analyzed.

0
Today / 11:41
|
877

Summit Therapeutics downgraded to neutral

H.C. Wainwright downgrades Summit Therapeutics to Neutral due to competitive pressure from Merck.

0
Today / 11:21
|
610

RBC Capital Initiates Essent Group at Sector Perform

RBC Capital starts Essent Group with Sector Perform, $68 target. Limited earnings growth expected through 2028, with ROE below 12%.

0
Today / 11:02
|
586

Dell Stock Rises on AI Momentum

Evercore ISI reaffirms Dell Outperform on AI momentum. Dell stock up 102% YTD, AI factory serves 5,000+ customers. New products unveiled.

0
Today / 11:01
|
411

Wolfe Research Starts Alto Neuroscience with Outperform

Wolfe Research initiates coverage on Alto Neuroscience with an outperform rating and $35 price target. ALTO-207 pipeline highlighted.

0
...